European stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased ...

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The co...

Demand for nutrition professionals is rapidly rising across India. Hospitals and digital health platforms are hiring more dietitians and ed...

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers...

Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo ...

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treati...

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individua...

Companies worldwide are experiencing a rise in AI-driven cyberattacks and ransomware incidents. Fairlife, a Coca-Cola-owned dairy company, ...

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...

Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to ...

Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.

In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...